GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TC Biopharm
TC Biopharm is a Scottish biotech company developing cell therapies. Its share price is highly speculative, reflecting its struggle to fund and advance its developments through clinical trials.
Share prices of companies in the market segment - Pharma immune
TC Biopharm is a Scottish biopharmaceutical company developing immunotherapeutics based on gamma-delta T cells for the treatment of cancer. We have classified it in the Pharma: Immunology category. The chart below shows how investors evaluate innovative approaches to cell therapy.
Broad Market Index - GURU.Markets
TC Biopharm is a Scottish biotech company developing allogeneic gamma-delta T-cell-based cell therapy for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how TC Biopharm shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TCBP - Daily change in the company's share price TC Biopharm
TC Biopharm (Holdings) PLC's daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its cell therapy clinical trials.
Daily change in the price of a set of shares in a market segment - Pharma immune
TC Biopharm is a biopharmaceutical company developing immunotherapy based on gamma-delta T cells. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating the highly volatile TCBP stock.
Daily change in the price of a broad market stock, index - GURU.Markets
TC Biopharm is a Scottish biotech company focused on immunology. Its US-listed shares bring the dynamics of the European biotech sector to the market. These international factors make the overall picture of market volatility more complex and global.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TC Biopharm
TC Biopharm (Holdings) plc's annual performance is a story about the development of its "off-the-shelf" cell therapy. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its gamma-delta T-cell approach could offer a new, more affordable way to treat blood cancer, its main scientific bet.
Annual dynamics of market capitalization of the market segment - Pharma immune
TC Biopharm, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TC Biopharm is an immuno-oncology company whose stock is betting on a new generation of cell therapy. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its platform. It's a high-risk play, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TC Biopharm
TC Biopharm is a Scottish biotech company developing cell therapies. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results for its gamma-delta T-cell platform are the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma immune
TC Biopharm is a clinical-stage biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is an innovative approach in immuno-oncology. The graph below shows the overall dynamics of the biotech sector, where the search for new types of T-cell therapy is a key focus.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TC Biopharm is a biotech company developing cell therapies for cancer treatment. Its stock is a classic venture capital story, where everything hinges on the success of clinical trials. Its performance is completely disconnected from the broader market and is determined by scientific breakthroughs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TC Biopharm
The weekly performance of TC Biopharm, a cell therapy company, reflects the hopes in immuno-oncology. Share prices are responding to clinical trial data from their "off-the-shelf" cell therapy, which could become a more affordable alternative to personalized therapies.
Weekly dynamics of market capitalization of the market segment - Pharma immune
TC Biopharm is developing a test-tube cell therapy for cancer treatment. This chart compares its volatile, data-driven performance with the immuno-oncology sector and helps us understand how much investor confidence in its platform compares to other cell therapy approaches.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TC Biopharm is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether TC Biopharm is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
TCBP - Market capitalization of the company TC Biopharm
The TC Biopharm market capitalization chart tells the story of a biotech company developing cell therapy. Its highly volatile performance at low levels tells the story of a struggle for survival, a constant search for funding, and the hope that its scientific research will one day lead to a breakthrough.
TCBP - Share of the company's market capitalization TC Biopharm within the market segment - Pharma immune
TC Biopharm is a biotech company developing cell-based cancer therapies. Its small market share reflects its early stage clinical development. The chart below is a barometer of investor hopes for the success of its immunotherapy approach.
Market capitalization of the market segment - Pharma immune
TC Biopharm is a clinical-stage biotech company developing cell therapies for cancer. The chart below shows the overall market capitalization of this sector. Its volatility reflects both the enormous hopes for a breakthrough in oncology and the high risks associated with clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
TC Biopharm is a biotech company developing cell therapy. The market capitalization of such companies reflects investors' faith in their scientific platform. Their volatility on the overall chart reflects the long and risky journey from the laboratory to a potential drug that could transform medicine.
Book value capitalization of the company, segment and market as a whole
TCBP - Book value capitalization of the company TC Biopharm
TC Biopharm's book value is its capital invested in developing a "ready-to-use" cell therapy (gamma-delta T cells) for the treatment of blood cancer. This provides a tangible, scientific foundation for the creation of universal and affordable cell-based medicines. How has this Scottish biotech asset changed? The chart below shows its dynamics.
TCBP - Share of the company's book capitalization TC Biopharm within the market segment - Pharma immune
TC Biopharm is developing cell therapy based on gamma-delta T cells. The chart shows the proportion of its unique laboratory and manufacturing assets, reflecting the physical foundation of this cutting-edge immuno-oncology platform.
Market segment balance sheet capitalization - Pharma immune
TC Biopharm, a cell therapy company, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that breakthrough research requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
TC Biopharm's balance sheet is its platform for developing gamma-delta T-cell-based cell therapy for the treatment of blood cancer. The company's assets include its intellectual capital, patents, and manufacturing capacity. The chart below shows the net worth of this pioneer in cellular immunotherapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TC Biopharm
TC Biopharm is a company developing cellular immunotherapy. Its balance sheet is its scientific developments. Its market capitalization is the sheer hope that its approach to cancer treatment will be successful. The MvsBCap_Co chart is a highly volatile indicator of investor faith in its scientific prospects.
Market to book capitalization ratio in a market segment - Pharma immune
TC Biopharm is a biotech company developing cell therapy for cancer based on gamma-delta T cells. Its market valuation on the chart is speculative and depends entirely on the success of its clinical programs and investor confidence in its scientific approach.
Market to book capitalization ratio for the market as a whole
TC Biopharm, a biopharmaceutical company focused on cell therapy, is valued by the market based on the potential of its scientific developments. This chart helps assess whether investor expectations for cutting-edge biotech trends are ahead of or behind overall market sentiment.
Debts of the company, segment and market as a whole
TCBP - Company debts TC Biopharm
TC Biopharm, a clinical-stage biotech developing cell therapies for cancer, is using capital to fund its research. This chart shows how the company is raising high-risk investments to advance its innovative platform, which could offer a new approach to immuno-oncology.
Market segment debts - Pharma immune
TC Biopharm is a clinical-stage biotech developing gamma-delta T-cell-based cell therapy. This chart demonstrates that the company, like its peers in the sector, relies solely on equity capital to fund its cutting-edge and risky research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TC Biopharm
TC Biopharm is a biotech company developing cell-based immunotherapy for cancer. This is a cutting-edge, but very expensive, field. This chart shows how much the company relies on debt to finance its clinical trials. It is a direct measure of its financial risk in developing a new treatment.
Market segment debt to market segment book capitalization - Pharma immune
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell immunotherapy for the treatment of cancer. This is an innovative approach to cell therapy. The chart shows how aggressively the sector uses debt, providing context for assessing how TC Biopharm is financing its risky but promising developments.
Debt to book value of all companies in the market
TC Biopharm, a biopharmaceutical company developing gamma-delta T-cell immunotherapy, is at the forefront of science, requiring massive investments. This chart, reflecting the overall market debt burden, helps assess the risks. It shows how the company is funding its breakthrough, yet high-risk, clinical trials.
P/E of the company, segment and market as a whole
P/E - TC Biopharm
TC Biopharm is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for the treatment of cancer. This chart shows how investors value its unique approach to cell therapy. The valuation is based on the potential of this technology.
P/E of the market segment - Pharma immune
Here's the average P/E for biotech companies. For TC Biopharm, which works in cell therapy, it serves as a benchmark. It reflects the overall level of investor faith in this cutting-edge but risky field of medicine, providing context for TC Biopharm's valuation, which is a bet on its unique scientific approach.
P/E of the market as a whole
TC Biopharm is a Scottish biotech company developing cell therapies for cancer treatment. Its valuation is a pure bet on its scientific platform and is unrelated to the general economic cycles depicted by this chart. TC Biopharm's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TC Biopharm
The chart for TC Biopharm (Holdings) PLC, a company developing gamma-delta T-cell-based immunotherapy, shows market expectations for its clinical trials. It reflects investor confidence in the potential of this unique platform for treating blood cancers and solid tumors.
%20P%2FE%20TC%20Biopharm&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TC-Biopharm&v=1772568461062 "Chart of the company's future (projected) P/E TC Biopharm")
Future (projected) P/E of the market segment - Pharma immune
TC Biopharm is a clinical-stage biopharmaceutical company developing allogeneic (donor) gamma-delta T-cell-based therapy for the treatment of blood cancers and solid tumors. The chart shows forecasts for the oncology sector. This helps compare how the market views TC Biopharm's innovative approach, which could offer a ready-to-use cell therapy, in its potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772568461101 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
TC Biopharm (Holdings) PLC is a Scottish biotech company developing cell-based cancer therapies. Its valuation depends on global investor interest in its developments. This chart, reflecting sentiment in the world's largest market, influences the availability of capital for smaller international biotech companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772568461127 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TC Biopharm
TC Biopharm is a clinical-stage biopharmaceutical company developing cancer immunotherapy based on gamma-delta T cells. Its financial results are determined by R&D losses. This chart shows the cost of developing an advanced cell therapy that could offer a new approach to cancer treatment.
Profit of companies in the market segment - Pharma immune
TC Biopharm is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This sector profitability chart illustrates how science is exploring new ways to harness the immune system. Their approach may offer a safer and more versatile "off-the-shelf" therapy than other cellular immunotherapies.
Overall market profit
TC Biopharm is a Scottish biopharmaceutical company developing gamma-delta T-cell-based cancer immunotherapy. This is an innovative approach to oncology. Like many early-stage biotechs, its valuation depends on the potential of the technology and research results. This total return chart reflects the investment climate, which is important for funding such companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TC Biopharm
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell-based cell therapy for the treatment of blood cancers and solid tumors. This chart reflects analysts' speculative expectations for the success of their unique platform in clinical trials, betting on a new approach in immuno-oncology.
%20profit%20of%20the%20company%20TC%20Biopharm&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TC-Biopharm&v=1772568461447 "Graph of future (projected) profit of the company TC Biopharm")
Future (predicted) profit of companies in the market segment - Pharma immune
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell-based cell therapies for the treatment of cancer and viral infections. The company's future depends on the success of its clinical programs. This chart for the oncology sector reflects the overall investor interest in innovative approaches to immunotherapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772568461501 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
TC Biopharm is developing immunotherapy based on gamma-delta T cells. Its future depends on success in clinical trials. The overall economic climate, illustrated by this chart, affects the availability of capital for biotech companies and their ability to fund expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772568461555 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TC Biopharm
TC Biopharm is a biotech company developing gamma-delta T-cell-based immunotherapy for cancer treatment. This chart is key for a clinical-stage company. It shows how investors view its unique scientific approach and future sales potential, placing their bets on this new type of cell therapy.
P/S market segment - Pharma immune
TC Biopharm is a biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for the treatment of cancer. The company's valuation is based on the future potential of this innovative cell therapy. This chart, which reflects the average valuation in the biotech industry, helps understand how investor expectations for TC Biopharm's scientific platform compare to overall trends.
P/S of the market as a whole
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell-based therapies for the treatment of cancer and viral infections. This chart, which reflects revenue estimates for real businesses, highlights that TC Biopharm's valuation is a bet on its unique approach to cellular immunotherapy and future clinical success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TC Biopharm
TC Biopharm is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is an innovative approach in immuno-oncology. This chart reflects investor hopes that its scientific platform will prove effective in the clinic and offer a new solution for cancer patients.
%20P%2FS%20TC%20Biopharm&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TC-Biopharm&v=1772568461681 "The graph of the company's future (projected) P/S TC Biopharm")
Future (projected) P/S of the market segment - Pharma immune
TC Biopharm (Holdings) PLC is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for the treatment of oncological and viral diseases. This chart reflects average revenue expectations in the biotechnology sector. It provides an insight into the market's perception of the potential of TC Biopharm's innovative cell therapy.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772568461711 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
TC Biopharm is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based therapies for the treatment of cancer. This graph reflects the market's overall revenue expectations. The company's innovative approach may offer new opportunities for cancer immunotherapy, fueling investor expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772568461771 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TC Biopharm
This chart illustrates the revenue of TC BioPharm, a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based cell therapy for the treatment of cancer. Its revenue at this stage is generated from grants and partnerships, reflecting progress in scientific research rather than sales.
Sales of companies in the market segment - Pharma immune
TC Biopharm is a biopharmaceutical company developing gamma-delta T-cell-based therapies for the treatment of cancer and viral infections. This chart shows the growth of the cellular immunotherapy market. The company's innovative "ready-to-use" approach could make cell therapy more accessible and faster than personalized methods.
Overall market sales
TC Biopharm is a biotech company developing immunotherapy based on gamma-delta T cells. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and the funding of advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TC Biopharm
TC BioPharm is a biotech company developing cancer immunotherapy based on unique cells—gamma-delta T cells. Future revenue depends on the success of this new approach in clinical trials. The chart reflects analysts' confidence in the potential of this cell therapy.
%20sales%20of%20the%20company%20TC%20Biopharm&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TC-Biopharm&v=1772568461873 "Schedule of future (projected) sales of the company TC Biopharm")
Future (projected) sales of companies in the market segment - Pharma immune
TC Biopharm is a biopharmaceutical company developing gamma-delta T-cell-based cell therapies for the treatment of cancer and viral infections. This chart shows the forecast for the entire immunotherapy market, where TC Biopharm aims to create universal, "ready-to-use" cell-based products that can treat a wide range of patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772568461900 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
TC Biopharm is a clinical-stage biotech company developing gamma-delta T-cell-based immunotherapy for cancer treatment. Its valuation is dependent on the success of clinical trials. This schedule, reflecting sentiment in the biotech sector, impacts the company's ability to attract funding to advance its unique cell therapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772568461927 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TC Biopharm
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in developing an innovative "live" therapy that could revolutionize immuno-oncology.
Market segment marginality - Pharma immune
TC Biopharm is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for the treatment of cancer. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential of this innovative cell therapy in oncology.
Market marginality as a whole
TC Biopharm is a Scottish biotech company developing a cell-based cancer therapy based on gamma-delta T cells. This is an innovative approach in immuno-oncology. This overall profitability schedule is irrelevant to them. Their value and future depend solely on the results of clinical trials and the potential of their scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company TC Biopharm
TC Biopharm is a clinical-stage biotechnology company developing cell therapies. Its team consists of scientists and manufacturing specialists. This timeline reflects its efforts to advance its complex therapeutic candidates through clinical trials.
Share of the company's employees TC Biopharm within the market segment - Pharma immune
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell-based cell therapy. This chart reflects its pioneering work. It shows the size of the team of scientists and manufacturing specialists working to create a "ready-to-use" cell therapy for cancer treatment, a complex but promising goal.
Number of employees in the market segment - Pharma immune
TC Biopharm (Holdings) PLC is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for the treatment of cancer. This chart shows the dynamics of employment in the cutting-edge field of cell therapy. The growing number of scientists here reflects progress in clinical research and the potential for creating a new, off-the-shelf treatment.
Number of employees in the market as a whole
TC Biopharm is a biotech company developing cell therapies for cancer treatment. Its development is entirely dependent on clinical trial results and capital raising. Overall economic stability, illustrated by this chart, influences investor willingness to invest in the high-risk biotech sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TC Biopharm (TCBP)
TC Biopharm is a Scottish biotech company developing cell therapy (CAR-T) based on gamma-delta T cells. This is an R&D business. The chart shows that the market value is a valuation of their scientific platform. The market capitalization per employee reflects investors' faith in the success of their cell therapy approach, not current revenue.
%20of%20the%20company%20TC%20Biopharm%20(TCBP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TC-Biopharm-TCBP&v=1772568462305 "Chart of market capitalization per employee (in thousands of dollars) of the company TC Biopharm (TCBP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
TC Biopharm is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. Its valuation is based on the potential of its innovative platform. This chart reflects the market's high valuation of its scientific developments and the potential of its small but highly qualified team of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772568462335 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
TC Biopharm is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based therapies for the treatment of cancer. The chart illustrates the market's perception of their unique approach to immunotherapy, which could become a new way to fight tumors.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772568462362 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TC Biopharm (TCBP)
TC Biopharm is a clinical-stage biotech company specializing in the development of gamma-delta T-cell therapy for cancer. This is R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist working on this cutting-edge cell therapy.
%20Chart%20TC%20Biopharm%20(TCBP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TC-Biopharm-TCBP&v=1772568462455 "Company Profit Per Employee (in thousands of dollars) Chart TC Biopharm (TCBP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
TC Biopharm is a clinical-stage biotechnology company developing cell therapies (gamma-delta T cells) for cancer treatment. This loss per employee reflects the high cost of R&D in this cutting-edge field of immuno-oncology.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772568462570 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
TC Biopharm (TCBP) is a clinical-stage biotech company specializing in cell therapy (Gamma Delta T-cells) for cancer treatment. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772568462576 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TC Biopharm (TCBP)
TC Biopharm is a biopharmaceutical company developing gamma-delta T-cell-based immunotherapy for cancer treatment. This chart reflects the early stages of commercialization of its platform. Growth in revenue per employee will indicate the success of clinical trials and interest from major pharmaceutical companies in its approach.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TC-Biopharm-TCBP&v=1772568462661 "Sales chart per company employee TC Biopharm (TCBP)")
Sales per employee in the market segment - Pharma immune
TC Biopharm (TCBP) is a biotech company developing cell therapies based on gamma-delta T cells (a type of immune cell) for the treatment of cancer. This chart shows how productive their R&D team is. It measures revenue (from partnerships or grants) per scientist, reflecting the value of their scientific platform.
Sales per employee for the market as a whole
TC Biopharm (TCBP) is a clinical-stage biotech company developing cell therapy (CAR-T) based on gamma-delta T cells. The company has no commercial revenue. This chart reflects a typical R&D situation: the research staff generates data and patents, but does not generate operating income.
Short shares by company, segment and market as a whole
Shares shorted by company TC Biopharm (TCBP)
TC Biopharm is a biotech company developing cell therapy (gamma-delta T cells). The bearish interest shown by this chart is a bet that this complex and expensive form of immunotherapy will fail to prove its effectiveness in clinical trials and will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TC-Biopharm-TCBP&v=1772568462889 "Short Shares Chart for the Company TC Biopharm (TCBP)")
Shares shorted by market segment - Pharma immune
TC Biopharm (TCBP) is a biotech company developing advanced immunotherapy (T-cells) for cancer treatment. This is one of the most complex and risky areas in medicine. This chart shows the total short position volume across the entire cell therapy sector. A high figure indicates widespread investor doubt about the clinical or commercial success of the entire industry.
Shares shorted by the overall market
TC Biopharm is a clinical-stage biotech company working on cell therapy. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like TCBP, preferring to cash out until the market calms down, without waiting for news on trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TC Biopharm (TCBP)
TC Biopharm (TCBP) is a Scottish biotech company developing cell therapy (gamma-delta T cells) for cancer treatment. This is a speculative area. This chart measures the strength of sharp price movements. It shows when bursts of enthusiasm (above 70) or periods of disappointment (below 30) peak, indicating a possible reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TC-Biopharm-TCBP&v=1772568463005 "RSI 14 indicator chart for the company's stock TC Biopharm (TCBP)")
RSI 14 Market Segment - Pharma immune
TC Biopharm is a UK biotech company, an immune system (Gamma Delta) engineer. They are developing universal (allogeneic) T-cell therapy (based on gamma-delta T cells) against cancer. The RSI_14_Seg index for "Pharma immune" (biotech) is driven by news. It shows the "temperature" of the entire segment. It helps us understand: is TCBP's growth due to their R&D, or is the entire biotech industry "overheated"?
RSI 14 for the overall market
TC Biopharm (TCBP) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TCBP (TC Biopharm)
TC Biopharm is a biotech company developing cell therapy (based on gamma-delta T cells) for the treatment of blood cancers. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TCBP-TC-Biopharm&v=1772568463124 "A chart showing analyst consensus forecasts for the expected stock price. TCBP (TC Biopharm)")
The difference between the consensus estimate and the actual stock price TCBP (TC Biopharm)
TC Biopharm (TCBP) is a biotech company pioneering the use of gamma-delta T cells—a unique type of immune cell—to treat blood cancers. This chart shows how far the current share price differs from its "fair" value. It reflects the "venture capital" valuation of analysts for this sophisticated R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TCBP-TC-Biopharm&v=1772568463180 "A chart showing the difference between the consensus forecast and the actual stock price. TCBP (TC Biopharm)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
TC Biopharm is a biotech company developing off-the-shelf cell therapies (gamma-delta T cells) for the treatment of blood cancers. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe a breakthrough in "universal" cell therapy is possible.
Analysts' consensus forecast for the overall market share price
TC Biopharm (TCBP) is a "ready-made" cell therapy company. It's a biotech company developing "allogeneic" (donor-derived) CAR-T cells for the treatment of blood cancer. This is highly speculative science. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TC Biopharm
TC Biopharm is a clinical-stage biotech company specializing in the development of cell therapies (Gamma Delta T cells) for the treatment of cancer and viral infections. It is a high-risk venture. This chart is a comprehensive barometer that attempts to assess the scientific potential of their platform, the risks of clinical trials, and the company's financial ability to bring research to fruition.
AKIMA Market Segment Index - Pharma immune
TC Biopharm (TCBP) is a pharma-immuno biotech company. They are developing cell therapy (Gamma-Delta T cells) that targets cancer and viral infections. They are at the cutting edge of R&D. This chart compares their composite index to the immunology sector average.
The AKIM Index for the overall market
TC Biopharm is a Scottish biotech company developing gamma-delta T-cell therapies for the treatment of cancer and infections. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative cell story fits into the context of overall economic trends.
